Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data BIODESIX INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
24.6
45.6
54.5
38.2
49.1
71.3
88.5
Research and development
10.5
10.8
12.8
13.1
9.99
9.56
12
Selling, general and administrative
30.6
34.9
50.5
61.5
67.4
80.5
87.5
Selling and marketing
7.2
7.57
7.56
Operating expenses
51.3
68.5
95.4
88.8
90.4
106
116
Operating income
-26.7
-22.9
-40.9
-50.6
-41.3
-34.5
-27.9
Interest expense
3.01
7.6
4.51
8.07
9.54
8.26
7.72
Interest income
0.06
0.02
Other non-operating income
-3.99
-8.42
-2.22
-14.9
-10.8
-8.43
-7.39
Income tax
0
0
0
0
0
0
Net income
-30.7
-65.4
-43.2
-65.4
-52.1
-42.9
-35.3
EBITDA
-23.9
-20
-37.8
-47
-38
-28.7
-22.2
EPS, basic
-2,555.00
-130.39
-31.79
-31.19
-12.88
-6.64
-4.67
EPS, diluted
-2,555.00
-130.39
-31.79
-31.19
-12.88
-6.64
-4.67
Shares, basic (weighted)
0.01
0.24
1.36
2.09
4.08
6.47
7.55
Shares, diluted (weighted)
0.01
0.24
1.36
2.09
4.08
6.47
7.55
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
5.29
62.1
32.7
43.1
26.3
26.2
19
Receivables
5.29
15.3
3.66
5.07
7.68
8.6
9.04
Other current assets
2.12
8.71
7.25
5.18
5.72
4.64
4.5
Total current assets
12.7
86.1
43.6
53.3
39.7
39.5
32.5
Property, plant and equipment
2.12
3.18
4.18
5.85
27.9
27.8
24.8
Lease right-of-use assets
1.5
2.97
1.75
1.77
3
Goodwill
15
15
15
15
15
15
15
Intangible assets
15.1
13.3
11.6
9.8
7.91
5.87
3.88
Other non-current assets
0.09
3.46
1.66
5.92
6.86
7.26
8.23
Total assets
45
121
76.1
92.9
99.1
97.2
87.5
Accounts payable
1.72
8.96
1.66
1.69
2.93
2.19
3.08
Accrued liabilities
4.18
7.79
7.67
8.22
7.71
10.1
11
Deferred revenue
1.28
3.53
1.85
0.96
0.32
0.68
0.96
Total current liabilities
22.6
32.1
29
22.8
33.4
14.3
17.4
Long-term debt
23.8
15.9
9.99
25
35.2
36.4
47.4
Lease liabilities
5.25
25.2
24.8
24
Other non-current liabilities
0.36
1.92
1.39
0.56
0.71
0.82
1.02
Total liabilities
76.2
79.9
56.4
72.3
94.5
76.4
89.9
Total debt
28.1
10.1
30.1
40.1
40
50
Paid-in capital
2.32
300
322
388
424
483
495
Retained earnings
-227
-259
-302
-367
-420
-462
-498
Shareholders' equity
-225
41.2
19.7
20.6
4.58
20.9
-2.47
Total equity
-225
41.2
19.7
20.6
4.58
20.9
-2.47
Total liabilities and equity
45
121
76.1
92.9
99.1
97.2
87.5
Shares outstanding
0.01
1.32
1.53
3.86
4.78
7.27
8.25
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-30.7
-31.4
-43.2
-65.4
-52.1
-42.9
-35.3
Depreciation and amortization
2.79
2.9
3.18
3.6
3.33
5.77
5.67
Stock-based compensation
0.17
3.71
4.94
5.96
5.37
6.64
4.14
Change in receivables
-3.65
-10.3
11.5
-1.5
-4.72
-1.81
-0.53
Change in payables
1.19
11.7
-7.43
-0.77
0.51
1.64
1.86
Cash from operations
-21.7
-21.4
-28.2
-45
-22.9
-48.6
-23.3
Capital expenditures
-1.31
-1.95
-2.24
-3.3
-22.9
-3.23
-0.26
Cash from investing
-1.87
-2.93
-2.55
-3.53
-23.1
-3.44
-0.4
Debt repaid
-45.4
-28.6
-0.05
-0.05
-0.02
Stock issued
0.05
1.34
16.3
59.5
28.1
55.6
7.32
Cash from financing
23
81.1
1.26
58.9
29.1
52.1
16.4
Net change in cash
-0.63
56.8
-29.5
10.4
-16.8
-0.04
-7.26
Free cash flow
-23
-23.3
-30.5
-48.3
-45.8
-51.9
-23.5
Interest paid
1.8
1.84
1.68
1.01
3.99
7.02
6.4
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $29.10 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-20.0%
Operating income / revenue.
EBITDA margin
-14.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-27.0%
Net income / revenue.
FCF margin
-19.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-19.3%
Cash from operations / revenue.
Return on equity (ROE)
-303.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-29.1%
Net income / average total assets.
Return on invested capital (ROIC)
-55.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
11.9%
Research and development expense / revenue.
SG&A / revenue
90.6%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
3.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.4%
Capital expenditures / revenue.
D&A / revenue
5.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
24.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
32.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
14.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-111.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-10.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-2.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-6.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
16.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
53.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
99.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.85x
Current assets / current liabilities.
Quick ratio
2.56x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.96x
(Cash + short-term investments) / current liabilities.
Debt / equity
5.47x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
52.5%
Total debt / total assets.
Liabilities / assets
90.4%
Total liabilities / total assets.
Net debt
$20.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$10.00
Revenue / diluted weighted shares.
FCF per share
-$1.97
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.93
Cash from operations / diluted weighted shares.
Book value per share
$0.87
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
2.98x
Market cap / revenue.
P/B
33.6x
Market cap / shareholders' equity. Only when equity is positive.
EV/Sales
3.18x
Enterprise value / revenue.
FCF yield
-6.6%
Free cash flow / market cap.
Earnings yield
-9.0%
Net income / market cap (the inverse of P/E).
What was BIODESIX INC's revenue in fiscal 2025?
BIODESIX INC reported revenue of $88.5M for fiscal 2025, 24.1% higher than the year before.
Was BIODESIX INC profitable in fiscal 2025?
No. It reported a net loss of $35.3M.
How much free cash flow did BIODESIX INC generate in fiscal 2025?
Cash from operations of $23.3M minus capital expenditures of $259.0K left free cash flow of -$23.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.